1. Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria; 2. Department of Cardiology, St.-Johannes-Hospital, Dortmund, Germany
Transcatheter aortic valve replacement (TAVR) has evolved from a last resort therapy to the standard treatment of patients with severe aortic stenosis and high risk for conventional surgery1 and has shown comparable outcomes in intermediate-risk patients2. Improvements to available transcatheter heart valves (THV), the introduction of new technologies, expansion of indication to lower-risk cohorts and increasing operator experience have resulted in a considerable decline in one-year mortality rates to below 10%3.
Despite these improvements, several issues remain to be addressed. Among these is the problem of new permanent pacemaker implantations (PPI) and new-onset conduction abnormalities (CA) after TAVI, which ...
Sign in to read and download the full articleForgot your password?
No account yet? Sign up for free!Create my pcr account
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
Read next articleData from real-world registries: can it guide development of the bioresorbable scaffolds of tomorrow?